Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arthroscopy tech assessment

This article was originally published in The Gray Sheet

Executive Summary

CMS will determine by Jan. 8 the indications for which arthroscopic lavage and/or debridement are "reasonable and necessary" for treating osteoarthritis of the knee, based on a review of data published in The New England Journal of Medicine suggesting the procedures are no more effective than placebo (1"The Gray Sheet" Sept. 2, 2002, p. 6). In early December, the Veterans Administration plans to release an internal review of whether recent study findings warrant limited coverage of the procedure...

You may also be interested in...

VA Reviewing Coverage Of Arthroscopic Knee Surgery; NEJM Study Debated

The Veterans Administration plans to complete within the next 90 days an internal review of whether recent study findings warrant continued coverage of arthroscopic knee surgical procedures to alleviate pain and stiffness caused by osteoarthritis

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit

US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts